Tissue Issues: A Deep Dive into Cutaneous Connective Tissue Disease

Cutaneous connective tissue diseases, particularly cutaneous lupus erythematosus (CLE) and dermatomyositis, present significant therapeutic challenges due to a lack of FDA-approved, standalone treatments. Deucravacitinib, a selective TIK2 inhibitor, demonstrates superior efficacy in CLE compared to placebo, with meta-analyses suggesting it outperforms other systemic therapies. Similarly, the anti-BDCA2 monoclonal antibody litofilumab shows promise in phase two trials, though clinical trial data for both remain limited by small sample sizes and high placebo response rates, potentially linked to improved patient adherence during study participation. For dermatomyositis, management relies on traditional agents like methotrexate and mycophenolate, alongside emerging JAK inhibitors like brepocitinib. Clinicians emphasize the necessity of rigorous malignancy screening and the difficulty of distinguishing between interface dermatoses, highlighting the ongoing need for standardized, sensitive outcome measures to better evaluate disease activity and treatment response in clinical practice.